In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Celgene Backs into Biotech

Executive Summary

A marketed product, a second in registration, and $300 million cash enabled Celgene to acquire a biotech capability and expand beyond its roots as a chiral chemistry company. But it took 15 years to get there. Formed as a bioremediation and chiral chemistry company in 1986, it struggled with those businesses. However, its chemical mentality led to in-licensing rights to thalidomide, which subsequently demonstrated activity in cancer. It reached profitability last year on sales of that drug, and with a chiral form of Ritalin pending approval, it finally had the resources to backfill a biology capability. Its purchase of Signal Pharmaceuticals gives it that and is its solution to the late-stage model problem of how to move beyond initial products and leverage a commercial infrastructure.

You may also be interested in...

Millennium: The Risks of Forward Integration

Millennium Pharmaceuticals has been spending much of the new century building a development organization. Much of this nuts-and-bolts endeavor came out of its acquisition of Cor Therapeutics in 2001, a transforming transaction that has delivered only mixed results, and has now put the company on a hard-to-steer and equally hard-to-alter course.

Thermo Fisher Scientific, Hillrom To Acquire Diagnostics Companies To Bolster Portfolios

Thermo Fisher Scientific has agreed to buy Mesa Biotech for $450m in cash and Hillrom will acquire Bardy Diagnostics for $375m in cash. Both deals will add complementary digital health solutions, which may be a continued trend in 2021.

Cosmetic And Personal Care Trademark Review 19 January, 2021

Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.


Related Companies




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts